Monitoring peripheral nerve degeneration in ALS by label-free stimulated Raman scattering imaging

The study of amyotrophic lateral sclerosis (ALS) and potential interventions would be facilitated if motor axon degeneration could be more readily visualized. Here we demonstrate that stimulated Raman scattering (SRS) microscopy could be used to sensitively monitor peripheral nerve degeneration in A...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Tian, Feng, Yang, Wenlong, Mordes, Daniel A, Wang, Jin-Yuan, Salameh, Johnny S, Mok, Joanie, Chew, Jeannie, Sharma, Aarti, Leno-Duran, Ester, Suzuki-Uematsu, Satomi, Suzuki, Naoki, Han, Steve S, Lu, Fa-Ke, Ji, Minbiao, Zhang, Rosanna, Liu, Yue, Strominger, Jack, Shneider, Neil A, Petrucelli, Leonard, Xie, X. Sunney, Eggan, Kevin
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The study of amyotrophic lateral sclerosis (ALS) and potential interventions would be facilitated if motor axon degeneration could be more readily visualized. Here we demonstrate that stimulated Raman scattering (SRS) microscopy could be used to sensitively monitor peripheral nerve degeneration in ALS mouse models and ALS autopsy materials. Three-dimensional imaging of pre-symptomatic SOD1 mouse models and data processing by a correlation-based algorithm revealed that significant degeneration of peripheral nerves could be detected coincidentally with the earliest detectable signs of muscle denervation and preceded physiologically measurable motor function decline. We also found that peripheral degeneration was an early event in FUS as well as C9ORF72 repeat expansion models of ALS, and that serial imaging allowed long-term observation of disease progression and drug effects in living animals. Our study demonstrates that SRS imaging is a sensitive and quantitative means of measuring disease progression, greatly facilitating future studies of disease mechanisms and candidate therapeutics.
ISSN:2041-1723
2041-1723
DOI:10.1038/ncomms13283